Nurix Therapeutics (NASDAQ:NRIX) Issues Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Nurix Therapeutics (NASDAQ:NRIX) posted its earnings results on Tuesday. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.08), Zacks reports. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%.

Nurix Therapeutics Stock Down 1.3 %

Nurix Therapeutics stock traded down $0.25 during mid-day trading on Tuesday, hitting $19.56. The company had a trading volume of 575,902 shares, compared to its average volume of 643,907. Nurix Therapeutics has a 1 year low of $7.65 and a 1 year high of $29.56. The business has a fifty day moving average of $20.26 and a 200 day moving average of $22.45. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of -6.72 and a beta of 2.14.

Analysts Set New Price Targets

A number of analysts recently issued reports on NRIX shares. HC Wainwright raised their price objective on Nurix Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Royal Bank of Canada dropped their target price on shares of Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, October 14th. Jefferies Financial Group initiated coverage on Nurix Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $41.00 price target on the stock. Stephens reaffirmed an “overweight” rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. Finally, UBS Group initiated coverage on shares of Nurix Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $35.00 target price on the stock. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $30.35.

Insider Transactions at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 2,368 shares of Nurix Therapeutics stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total value of $57,542.40. Following the transaction, the chief financial officer now directly owns 37,270 shares of the company’s stock, valued at $905,661. The trade was a 5.97 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Gwenn Hansen sold 3,437 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $24.30, for a total transaction of $83,519.10. Following the sale, the insider now owns 50,670 shares of the company’s stock, valued at approximately $1,231,281. This represents a 6.35 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 9,351 shares of company stock worth $227,158. 7.20% of the stock is currently owned by insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.